Abstract
Understanding of the full potential of the genome coding capacity demands a deep knowledge of the different pathways that control gene expression. Translation initiation in eukaryotic mRNAs is a highly regulated process that accounts for the last step of gene expression control. While most mRNAs initiate translation using the AUG triplet closest to the 5end, a growing number of mRNAs appear to follow different rules, giving rise to proteins that differ in their amino terminus. Internal ribosome entry site (IRES) elements provide an alternative to initiate translation that allow the use of internal start codons, sometimes located several hundred of residues away from the 5end of the mRNA, bypassing strong RNA structures. Therefore, they represent a strategy to increase genetic diversity without increasing genome length. The IRES sequences found in viral and cellular mRNAs do not show overall sequence similarity, albeit they perform a similar function. IRES elements in viral mRNAs constitute an efficient method to distinguish its own mRNA from that of the host, and thus facilitate its survival when cellular protein synthesis is impaired. Viral IRES exploit different strategies to recruit the translational machinery, including direct ribosome binding, eIF3 or eIF4G-mediated mechanism. Cellular IRES mediated-translation represents a regulatory mechanism that helps the cell to cope with transient stress. They may be grouped according to common tropism, stimulation by similar situations and expression of specific targets in differentiated cells. Protein mediated-ribosome binding is likely to enhance the efficiency of cellular IRES sequences under specific environments. This review is focused to discuss recent advances on functional IRES elements.
Keywords: mrna, ires, protein synthesis, new orfs, genetic diversity, eukaryotic genomes
Current Genomics
Title: Internal Ribosome Entry Site Elements in Eukaryotic Genomes
Volume: 5 Issue: 3
Author(s): E. Martinez-Salas, O. Fernandez-Miragall, R. Reigadas, A. Pacheco and P. Serrano
Affiliation:
Keywords: mrna, ires, protein synthesis, new orfs, genetic diversity, eukaryotic genomes
Abstract: Understanding of the full potential of the genome coding capacity demands a deep knowledge of the different pathways that control gene expression. Translation initiation in eukaryotic mRNAs is a highly regulated process that accounts for the last step of gene expression control. While most mRNAs initiate translation using the AUG triplet closest to the 5end, a growing number of mRNAs appear to follow different rules, giving rise to proteins that differ in their amino terminus. Internal ribosome entry site (IRES) elements provide an alternative to initiate translation that allow the use of internal start codons, sometimes located several hundred of residues away from the 5end of the mRNA, bypassing strong RNA structures. Therefore, they represent a strategy to increase genetic diversity without increasing genome length. The IRES sequences found in viral and cellular mRNAs do not show overall sequence similarity, albeit they perform a similar function. IRES elements in viral mRNAs constitute an efficient method to distinguish its own mRNA from that of the host, and thus facilitate its survival when cellular protein synthesis is impaired. Viral IRES exploit different strategies to recruit the translational machinery, including direct ribosome binding, eIF3 or eIF4G-mediated mechanism. Cellular IRES mediated-translation represents a regulatory mechanism that helps the cell to cope with transient stress. They may be grouped according to common tropism, stimulation by similar situations and expression of specific targets in differentiated cells. Protein mediated-ribosome binding is likely to enhance the efficiency of cellular IRES sequences under specific environments. This review is focused to discuss recent advances on functional IRES elements.
Export Options
About this article
Cite this article as:
Martinez-Salas E., Fernandez-Miragall O., Reigadas R., Pacheco A. and Serrano P., Internal Ribosome Entry Site Elements in Eukaryotic Genomes, Current Genomics 2004; 5 (3) . https://dx.doi.org/10.2174/1389202043349390
DOI https://dx.doi.org/10.2174/1389202043349390 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Clinical Significance of Breast Cancer Resistance Protein/ABCG2 in the Management of Malignancy
Clinical Cancer Drugs LRP/LR as an Alternative Promising Target in Therapy of Prion Diseases, Alzheimers Disease and Cancer
Infectious Disorders - Drug Targets Can the Use of HIV-1 Derived Gene Transfer Vectors for Clinical Application be Justified?
Current Gene Therapy Redox Homeostasis, Bioactive Agents and Transduction Therapy
Current Signal Transduction Therapy Vybrant DyeCycle Violet Stain Discriminates Two Different Subsets of CD34+ Cells
Current Stem Cell Research & Therapy Role of Genetics and Epigenetics in Mucosal, Uveal, and Cutaneous Melanomagenesis
Anti-Cancer Agents in Medicinal Chemistry Recent Patents in Antiviral siRNAs
Recent Patents on Anti-Infective Drug Discovery Huntingtons Disease: New Frontiers for Molecular and Cell Therapy
Current Drug Targets Inhibition of Protein Kinase c-Src as a Therapeutic Approach for Cancer and Bone Metastases
Anti-Cancer Agents in Medicinal Chemistry HLA Peptide-mediated Strategies for Modulation of Cellular and Humoral Immune Response in Transplantation
Current Pharmacogenomics FLT3 Inhibitors in the Management of Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Drugging Cell Cycle Kinases in Cancer Therapy
Current Drug Targets Immunotherapy of Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Liposomes as Versatile Platform for Cancer Theranostics: Therapy, Bio-imaging, and Toxicological Aspects
Current Pharmaceutical Design Functional Nanoplatforms for Enhancement of Chemotherapeutic Index
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Activation of Protein Phosphatase 2 A (PP2A): A Novel Strategy to Fight Against Human Malignancies?
Current Medicinal Chemistry Chromatin Remodeling Agents for Cancer Therapy
Reviews on Recent Clinical Trials Naturally Occurring δ-Hydroxy-γ-Lactones: Muricatacins and Related Compounds
Current Organic Chemistry Personalized Medicine in Oncology: A Personal View with Myths and Facts
Current Clinical Pharmacology